nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—TYMS—colon cancer	0.171	0.798	CbGaD
Methotrexate—breast cancer—colon cancer	0.153	0.398	CtDrD
Methotrexate—stomach cancer—colon cancer	0.132	0.343	CtDrD
Methotrexate—lung cancer—colon cancer	0.0995	0.259	CtDrD
Methotrexate—TYMS—Capecitabine—colon cancer	0.0545	0.191	CbGbCtD
Methotrexate—ABCB1—colon cancer	0.0435	0.202	CbGaD
Methotrexate—MTHFR—Fluorouracil—colon cancer	0.0379	0.133	CbGbCtD
Methotrexate—TYMS—Fluorouracil—colon cancer	0.0323	0.113	CbGbCtD
Methotrexate—ABCC10—Vincristine—colon cancer	0.0243	0.0849	CbGbCtD
Methotrexate—ABCC3—Fluorouracil—colon cancer	0.0168	0.0586	CbGbCtD
Methotrexate—ABCC3—Vincristine—colon cancer	0.0153	0.0534	CbGbCtD
Methotrexate—SLC22A7—Fluorouracil—colon cancer	0.0131	0.0458	CbGbCtD
Methotrexate—ABCC4—Fluorouracil—colon cancer	0.0128	0.0448	CbGbCtD
Methotrexate—ABCC1—Irinotecan—colon cancer	0.0107	0.0375	CbGbCtD
Methotrexate—ABCC1—Vincristine—colon cancer	0.00937	0.0328	CbGbCtD
Methotrexate—SLCO1B1—Irinotecan—colon cancer	0.00903	0.0316	CbGbCtD
Methotrexate—ABCC2—Irinotecan—colon cancer	0.00793	0.0278	CbGbCtD
Methotrexate—ABCG2—Irinotecan—colon cancer	0.00717	0.0251	CbGbCtD
Methotrexate—ABCC2—Vincristine—colon cancer	0.00693	0.0243	CbGbCtD
Methotrexate—ABCG2—Fluorouracil—colon cancer	0.00688	0.0241	CbGbCtD
Methotrexate—ABCG2—Vincristine—colon cancer	0.00627	0.0219	CbGbCtD
Methotrexate—ALB—Irinotecan—colon cancer	0.00494	0.0173	CbGbCtD
Methotrexate—ALB—Fluorouracil—colon cancer	0.00475	0.0166	CbGbCtD
Methotrexate—ABCB1—Irinotecan—colon cancer	0.00259	0.00905	CbGbCtD
Methotrexate—ABCB1—Vincristine—colon cancer	0.00226	0.00791	CbGbCtD
Methotrexate—ABCC2—bile—colon cancer	0.00136	0.0389	CbGeAlD
Methotrexate—ABCC11—embryo—colon cancer	0.000915	0.0262	CbGeAlD
Methotrexate—Raltitrexed—TYMS—colon cancer	0.000795	0.32	CrCbGaD
Methotrexate—FOLR1—epithelium—colon cancer	0.000779	0.0223	CbGeAlD
Methotrexate—FOLR1—renal system—colon cancer	0.000722	0.0207	CbGeAlD
Methotrexate—MTHFR—blood vessel—colon cancer	0.000672	0.0192	CbGeAlD
Methotrexate—Leucovorin—TYMS—colon cancer	0.000603	0.243	CrCbGaD
Methotrexate—Pralatrexate—TYMS—colon cancer	0.000603	0.243	CrCbGaD
Methotrexate—FOLR1—lymphoid tissue—colon cancer	0.0006	0.0172	CbGeAlD
Methotrexate—ATIC—embryo—colon cancer	0.000539	0.0154	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—colon cancer	0.000526	0.015	CbGeAlD
Methotrexate—SLC19A1—digestive system—colon cancer	0.000519	0.0149	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—colon cancer	0.000499	0.0143	CbGeAlD
Methotrexate—AOX1—gall bladder—colon cancer	0.000484	0.0138	CbGeAlD
Methotrexate—Pemetrexed—TYMS—colon cancer	0.000482	0.194	CrCbGaD
Methotrexate—GGH—renal system—colon cancer	0.00048	0.0137	CbGeAlD
Methotrexate—ABCC3—gall bladder—colon cancer	0.000473	0.0135	CbGeAlD
Methotrexate—ATIC—epithelium—colon cancer	0.00044	0.0126	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vincristine—colon cancer	0.000438	0.593	CbGdCrCtD
Methotrexate—SLCO4C1—renal system—colon cancer	0.000426	0.0122	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—colon cancer	0.000424	0.0121	CbGeAlD
Methotrexate—ABCC11—liver—colon cancer	0.000423	0.0121	CbGeAlD
Methotrexate—ATIC—renal system—colon cancer	0.000408	0.0117	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—colon cancer	0.000405	0.0116	CbGeAlD
Methotrexate—ALB—gall bladder—colon cancer	0.000403	0.0115	CbGeAlD
Methotrexate—SLC46A1—digestive system—colon cancer	0.0004	0.0114	CbGeAlD
Methotrexate—GGH—digestive system—colon cancer	0.000394	0.0113	CbGeAlD
Methotrexate—SLC19A1—liver—colon cancer	0.000387	0.0111	CbGeAlD
Methotrexate—GGH—bone marrow—colon cancer	0.000363	0.0104	CbGeAlD
Methotrexate—DHFR—embryo—colon cancer	0.000362	0.0104	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—colon cancer	0.00035	0.01	CbGeAlD
Methotrexate—GGH—vagina—colon cancer	0.000348	0.00994	CbGeAlD
Methotrexate—FPGS—digestive system—colon cancer	0.000346	0.0099	CbGeAlD
Methotrexate—SLCO1C1—renal system—colon cancer	0.000339	0.0097	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—colon cancer	0.000339	0.00969	CbGeAlD
Methotrexate—ATIC—digestive system—colon cancer	0.000335	0.00957	CbGeAlD
Methotrexate—SLC22A11—renal system—colon cancer	0.000329	0.00942	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—colon cancer	0.000322	0.0092	CbGeAlD
Methotrexate—SLC22A7—renal system—colon cancer	0.000322	0.0092	CbGeAlD
Methotrexate—SLCO4C1—vagina—colon cancer	0.000308	0.00882	CbGeAlD
Methotrexate—FPGS—vagina—colon cancer	0.000306	0.00874	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vincristine—colon cancer	0.000301	0.407	CbGdCrCtD
Methotrexate—SLCO1B3—vagina—colon cancer	0.0003	0.00857	CbGeAlD
Methotrexate—SLCO3A1—renal system—colon cancer	0.000298	0.00854	CbGeAlD
Methotrexate—SLC46A1—liver—colon cancer	0.000298	0.00853	CbGeAlD
Methotrexate—SLC19A1—lymph node—colon cancer	0.000297	0.00849	CbGeAlD
Methotrexate—GGH—liver—colon cancer	0.000293	0.00839	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—colon cancer	0.000287	0.00822	CbGeAlD
Methotrexate—DHFR—renal system—colon cancer	0.000274	0.00784	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—colon cancer	0.000274	0.00783	CbGeAlD
Methotrexate—SLC22A11—digestive system—colon cancer	0.00027	0.00773	CbGeAlD
Methotrexate—SLC16A1—epithelium—colon cancer	0.000265	0.00758	CbGeAlD
Methotrexate—SLC22A7—digestive system—colon cancer	0.000264	0.00754	CbGeAlD
Methotrexate—PGD—renal system—colon cancer	0.000263	0.00753	CbGeAlD
Methotrexate—SLCO4C1—liver—colon cancer	0.00026	0.00744	CbGeAlD
Methotrexate—FPGS—liver—colon cancer	0.000258	0.00737	CbGeAlD
Methotrexate—SLCO1B3—liver—colon cancer	0.000253	0.00723	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—colon cancer	0.000252	0.0072	CbGeAlD
Methotrexate—ATIC—liver—colon cancer	0.000249	0.00713	CbGeAlD
Methotrexate—MTHFR—digestive system—colon cancer	0.000249	0.00711	CbGeAlD
Methotrexate—SLC16A1—renal system—colon cancer	0.000246	0.00703	CbGeAlD
Methotrexate—SLCO1B1—renal system—colon cancer	0.000239	0.00684	CbGeAlD
Methotrexate—AOX1—renal system—colon cancer	0.000232	0.00664	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—colon cancer	0.00023	0.00657	CbGeAlD
Methotrexate—SLC46A1—lymph node—colon cancer	0.000229	0.00654	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—colon cancer	0.000228	0.00651	CbGeAlD
Methotrexate—TYMS—digestive system—colon cancer	0.000227	0.00649	CbGeAlD
Methotrexate—ABCC3—renal system—colon cancer	0.000227	0.00649	CbGeAlD
Methotrexate—ABCC10—renal system—colon cancer	0.000226	0.00646	CbGeAlD
Methotrexate—GGH—lymph node—colon cancer	0.000225	0.00643	CbGeAlD
Methotrexate—DHFR—digestive system—colon cancer	0.000225	0.00643	CbGeAlD
Methotrexate—PGD—lymphoid tissue—colon cancer	0.000219	0.00626	CbGeAlD
Methotrexate—SLCO3A1—vagina—colon cancer	0.000216	0.00618	CbGeAlD
Methotrexate—PGD—digestive system—colon cancer	0.000216	0.00618	CbGeAlD
Methotrexate—TYMS—bone marrow—colon cancer	0.000209	0.00598	CbGeAlD
Methotrexate—DHFR—bone marrow—colon cancer	0.000207	0.00593	CbGeAlD
Methotrexate—SLC16A1—digestive system—colon cancer	0.000202	0.00577	CbGeAlD
Methotrexate—SLC22A11—liver—colon cancer	0.000201	0.00576	CbGeAlD
Methotrexate—TYMS—vagina—colon cancer	0.0002	0.00573	CbGeAlD
Methotrexate—PGD—bone marrow—colon cancer	0.000199	0.0057	CbGeAlD
Methotrexate—DHFR—vagina—colon cancer	0.000198	0.00568	CbGeAlD
Methotrexate—FPGS—lymph node—colon cancer	0.000198	0.00565	CbGeAlD
Methotrexate—SLC22A7—liver—colon cancer	0.000197	0.00562	CbGeAlD
Methotrexate—SLCO1B1—digestive system—colon cancer	0.000196	0.00561	CbGeAlD
Methotrexate—SLCO1A2—renal system—colon cancer	0.000195	0.00557	CbGeAlD
Methotrexate—ATIC—lymph node—colon cancer	0.000191	0.00547	CbGeAlD
Methotrexate—PGD—vagina—colon cancer	0.000191	0.00546	CbGeAlD
Methotrexate—AOX1—digestive system—colon cancer	0.00019	0.00544	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—colon cancer	0.000188	0.00536	CbGeAlD
Methotrexate—ABCC4—renal system—colon cancer	0.000187	0.00536	CbGeAlD
Methotrexate—ABCC3—digestive system—colon cancer	0.000186	0.00532	CbGeAlD
Methotrexate—SLC22A8—renal system—colon cancer	0.000186	0.00532	CbGeAlD
Methotrexate—MTHFR—liver—colon cancer	0.000185	0.0053	CbGeAlD
Methotrexate—ABCC10—digestive system—colon cancer	0.000185	0.0053	CbGeAlD
Methotrexate—SLCO3A1—liver—colon cancer	0.000182	0.00522	CbGeAlD
Methotrexate—ABCC2—renal system—colon cancer	0.000181	0.00519	CbGeAlD
Methotrexate—ABCC10—bone marrow—colon cancer	0.000171	0.00488	CbGeAlD
Methotrexate—TYMS—liver—colon cancer	0.000169	0.00484	CbGeAlD
Methotrexate—AOX1—vagina—colon cancer	0.000168	0.00481	CbGeAlD
Methotrexate—DHFR—liver—colon cancer	0.000167	0.00479	CbGeAlD
Methotrexate—ABCC10—vagina—colon cancer	0.000164	0.00468	CbGeAlD
Methotrexate—PGD—liver—colon cancer	0.000161	0.0046	CbGeAlD
Methotrexate—SLCO1A2—digestive system—colon cancer	0.00016	0.00457	CbGeAlD
Methotrexate—SLCO1C1—lymph node—colon cancer	0.000159	0.00455	CbGeAlD
Methotrexate—ABCC4—digestive system—colon cancer	0.000154	0.0044	CbGeAlD
Methotrexate—SLC16A1—liver—colon cancer	0.00015	0.0043	CbGeAlD
Methotrexate—ABCC2—digestive system—colon cancer	0.000149	0.00425	CbGeAlD
Methotrexate—SLCO1B1—liver—colon cancer	0.000146	0.00418	CbGeAlD
Methotrexate—ABCB1—blood vessel—colon cancer	0.000144	0.00413	CbGeAlD
Methotrexate—MTHFR—lymph node—colon cancer	0.000142	0.00406	CbGeAlD
Methotrexate—AOX1—liver—colon cancer	0.000142	0.00406	CbGeAlD
Methotrexate—ABCC4—bone marrow—colon cancer	0.000142	0.00405	CbGeAlD
Methotrexate—SLCO3A1—lymph node—colon cancer	0.00014	0.004	CbGeAlD
Methotrexate—ABCC3—liver—colon cancer	0.000139	0.00397	CbGeAlD
Methotrexate—ABCC10—liver—colon cancer	0.000138	0.00395	CbGeAlD
Methotrexate—TYMS—lymph node—colon cancer	0.00013	0.00371	CbGeAlD
Methotrexate—DHFR—lymph node—colon cancer	0.000128	0.00367	CbGeAlD
Methotrexate—PGD—lymph node—colon cancer	0.000123	0.00353	CbGeAlD
Methotrexate—SLCO1A2—liver—colon cancer	0.000119	0.0034	CbGeAlD
Methotrexate—ALB—liver—colon cancer	0.000118	0.00338	CbGeAlD
Methotrexate—ABCC1—vagina—colon cancer	0.000116	0.00331	CbGeAlD
Methotrexate—SLC16A1—lymph node—colon cancer	0.000115	0.0033	CbGeAlD
Methotrexate—ABCC4—liver—colon cancer	0.000114	0.00327	CbGeAlD
Methotrexate—ABCC2—liver—colon cancer	0.000111	0.00317	CbGeAlD
Methotrexate—Eosinophilia—Fluorouracil—colon cancer	0.000109	0.00202	CcSEcCtD
Methotrexate—Erectile dysfunction—Vincristine—colon cancer	0.000109	0.00202	CcSEcCtD
Methotrexate—AOX1—lymph node—colon cancer	0.000109	0.00311	CbGeAlD
Methotrexate—Photosensitivity reaction—Vincristine—colon cancer	0.000108	0.002	CcSEcCtD
Methotrexate—Neutropenia—Irinotecan—colon cancer	0.000108	0.00199	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Irinotecan—colon cancer	0.000107	0.00198	CcSEcCtD
Methotrexate—Sepsis—Capecitabine—colon cancer	0.000107	0.00197	CcSEcCtD
Methotrexate—ABCC3—lymph node—colon cancer	0.000106	0.00304	CbGeAlD
Methotrexate—Pneumonia—Vincristine—colon cancer	0.000106	0.00196	CcSEcCtD
Methotrexate—ABCC10—lymph node—colon cancer	0.000106	0.00303	CbGeAlD
Methotrexate—Depression—Vincristine—colon cancer	0.000105	0.00195	CcSEcCtD
Methotrexate—Pancytopenia—Fluorouracil—colon cancer	0.000105	0.00194	CcSEcCtD
Methotrexate—Pneumonia—Irinotecan—colon cancer	0.000104	0.00191	CcSEcCtD
Methotrexate—Thrombophlebitis—Capecitabine—colon cancer	0.000103	0.00191	CcSEcCtD
Methotrexate—Stomatitis—Vincristine—colon cancer	0.000103	0.0019	CcSEcCtD
Methotrexate—Diabetes mellitus—Capecitabine—colon cancer	0.000103	0.0019	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000103	0.0019	CcSEcCtD
Methotrexate—Photosensitivity—Capecitabine—colon cancer	0.000102	0.00188	CcSEcCtD
Methotrexate—Polyuria—Capecitabine—colon cancer	0.000102	0.00188	CcSEcCtD
Methotrexate—Sweating—Vincristine—colon cancer	0.000101	0.00187	CcSEcCtD
Methotrexate—Renal failure—Irinotecan—colon cancer	0.000101	0.00187	CcSEcCtD
Methotrexate—Photosensitivity reaction—Fluorouracil—colon cancer	0.000101	0.00186	CcSEcCtD
Methotrexate—Stomatitis—Irinotecan—colon cancer	0.0001	0.00185	CcSEcCtD
Methotrexate—ABCG2—bone marrow—colon cancer	0.0001	0.00286	CbGeAlD
Methotrexate—Hepatic failure—Capecitabine—colon cancer	9.95e-05	0.00184	CcSEcCtD
Methotrexate—Pneumonia—Fluorouracil—colon cancer	9.91e-05	0.00183	CcSEcCtD
Methotrexate—Sweating—Irinotecan—colon cancer	9.87e-05	0.00182	CcSEcCtD
Methotrexate—Infestation NOS—Fluorouracil—colon cancer	9.86e-05	0.00182	CcSEcCtD
Methotrexate—Infestation—Fluorouracil—colon cancer	9.86e-05	0.00182	CcSEcCtD
Methotrexate—ABCC1—liver—colon cancer	9.76e-05	0.00279	CbGeAlD
Methotrexate—Renal failure acute—Capecitabine—colon cancer	9.68e-05	0.00179	CcSEcCtD
Methotrexate—Stomatitis—Fluorouracil—colon cancer	9.61e-05	0.00178	CcSEcCtD
Methotrexate—Conjunctivitis—Fluorouracil—colon cancer	9.58e-05	0.00177	CcSEcCtD
Methotrexate—ABCG2—vagina—colon cancer	9.58e-05	0.00274	CbGeAlD
Methotrexate—Dermatitis exfoliative—Capecitabine—colon cancer	9.47e-05	0.00175	CcSEcCtD
Methotrexate—Urinary tract disorder—Vincristine—colon cancer	9.37e-05	0.00173	CcSEcCtD
Methotrexate—Urethral disorder—Vincristine—colon cancer	9.3e-05	0.00172	CcSEcCtD
Methotrexate—Epistaxis—Fluorouracil—colon cancer	9.3e-05	0.00172	CcSEcCtD
Methotrexate—Haemoglobin—Irinotecan—colon cancer	9.29e-05	0.00172	CcSEcCtD
Methotrexate—Haemorrhage—Irinotecan—colon cancer	9.24e-05	0.00171	CcSEcCtD
Methotrexate—Agranulocytosis—Fluorouracil—colon cancer	9.2e-05	0.0017	CcSEcCtD
Methotrexate—Cerebrovascular accident—Capecitabine—colon cancer	9.12e-05	0.00169	CcSEcCtD
Methotrexate—Lethargy—Capecitabine—colon cancer	9.12e-05	0.00169	CcSEcCtD
Methotrexate—ALB—lymph node—colon cancer	9.07e-05	0.00259	CbGeAlD
Methotrexate—Osteoarthritis—Capecitabine—colon cancer	8.94e-05	0.00165	CcSEcCtD
Methotrexate—Visual impairment—Irinotecan—colon cancer	8.9e-05	0.00165	CcSEcCtD
Methotrexate—Haemoglobin—Fluorouracil—colon cancer	8.89e-05	0.00164	CcSEcCtD
Methotrexate—Haemorrhage—Fluorouracil—colon cancer	8.85e-05	0.00164	CcSEcCtD
Methotrexate—Cardiac disorder—Vincristine—colon cancer	8.8e-05	0.00163	CcSEcCtD
Methotrexate—Pharyngitis—Fluorouracil—colon cancer	8.78e-05	0.00162	CcSEcCtD
Methotrexate—ABCC4—lymph node—colon cancer	8.78e-05	0.00251	CbGeAlD
Methotrexate—ABCB1—embryo—colon cancer	8.62e-05	0.00246	CbGeAlD
Methotrexate—Angiopathy—Vincristine—colon cancer	8.61e-05	0.00159	CcSEcCtD
Methotrexate—Cardiac disorder—Irinotecan—colon cancer	8.57e-05	0.00158	CcSEcCtD
Methotrexate—Mediastinal disorder—Vincristine—colon cancer	8.55e-05	0.00158	CcSEcCtD
Methotrexate—Irritability—Capecitabine—colon cancer	8.53e-05	0.00158	CcSEcCtD
Methotrexate—ABCC2—lymph node—colon cancer	8.5e-05	0.00243	CbGeAlD
Methotrexate—Mood swings—Capecitabine—colon cancer	8.47e-05	0.00156	CcSEcCtD
Methotrexate—Ataxia—Capecitabine—colon cancer	8.4e-05	0.00155	CcSEcCtD
Methotrexate—Alopecia—Vincristine—colon cancer	8.38e-05	0.00155	CcSEcCtD
Methotrexate—Angiopathy—Irinotecan—colon cancer	8.38e-05	0.00155	CcSEcCtD
Methotrexate—Immune system disorder—Irinotecan—colon cancer	8.35e-05	0.00154	CcSEcCtD
Methotrexate—Mediastinal disorder—Irinotecan—colon cancer	8.33e-05	0.00154	CcSEcCtD
Methotrexate—Mental disorder—Vincristine—colon cancer	8.31e-05	0.00154	CcSEcCtD
Methotrexate—Chills—Irinotecan—colon cancer	8.29e-05	0.00153	CcSEcCtD
Methotrexate—Liver function test abnormal—Capecitabine—colon cancer	8.25e-05	0.00152	CcSEcCtD
Methotrexate—Alopecia—Irinotecan—colon cancer	8.16e-05	0.00151	CcSEcCtD
Methotrexate—ABCG2—liver—colon cancer	8.08e-05	0.00231	CbGeAlD
Methotrexate—Breast disorder—Capecitabine—colon cancer	8.08e-05	0.00149	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Capecitabine—colon cancer	8.05e-05	0.00149	CcSEcCtD
Methotrexate—Back pain—Vincristine—colon cancer	7.99e-05	0.00148	CcSEcCtD
Methotrexate—Alopecia—Fluorouracil—colon cancer	7.82e-05	0.00144	CcSEcCtD
Methotrexate—Back pain—Irinotecan—colon cancer	7.78e-05	0.00144	CcSEcCtD
Methotrexate—Asthma—Capecitabine—colon cancer	7.73e-05	0.00143	CcSEcCtD
Methotrexate—Erythema—Fluorouracil—colon cancer	7.7e-05	0.00142	CcSEcCtD
Methotrexate—Anaemia—Vincristine—colon cancer	7.63e-05	0.00141	CcSEcCtD
Methotrexate—ABCC1—lymph node—colon cancer	7.48e-05	0.00214	CbGeAlD
Methotrexate—Ill-defined disorder—Irinotecan—colon cancer	7.46e-05	0.00138	CcSEcCtD
Methotrexate—Anaemia—Irinotecan—colon cancer	7.43e-05	0.00137	CcSEcCtD
Methotrexate—Vertigo—Vincristine—colon cancer	7.42e-05	0.00137	CcSEcCtD
Methotrexate—Abdominal discomfort—Capecitabine—colon cancer	7.41e-05	0.00137	CcSEcCtD
Methotrexate—Leukopenia—Vincristine—colon cancer	7.39e-05	0.00137	CcSEcCtD
Methotrexate—Pancytopenia—Capecitabine—colon cancer	7.34e-05	0.00136	CcSEcCtD
Methotrexate—Vision blurred—Fluorouracil—colon cancer	7.26e-05	0.00134	CcSEcCtD
Methotrexate—Malaise—Irinotecan—colon cancer	7.25e-05	0.00134	CcSEcCtD
Methotrexate—Vertigo—Irinotecan—colon cancer	7.23e-05	0.00134	CcSEcCtD
Methotrexate—Neutropenia—Capecitabine—colon cancer	7.22e-05	0.00133	CcSEcCtD
Methotrexate—Dysuria—Capecitabine—colon cancer	7.22e-05	0.00133	CcSEcCtD
Methotrexate—Leukopenia—Irinotecan—colon cancer	7.2e-05	0.00133	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Capecitabine—colon cancer	7.18e-05	0.00133	CcSEcCtD
Methotrexate—Convulsion—Vincristine—colon cancer	7.16e-05	0.00132	CcSEcCtD
Methotrexate—Anaemia—Fluorouracil—colon cancer	7.12e-05	0.00132	CcSEcCtD
Methotrexate—Photosensitivity reaction—Capecitabine—colon cancer	7.05e-05	0.0013	CcSEcCtD
Methotrexate—ABCB1—epithelium—colon cancer	7.03e-05	0.00201	CbGeAlD
Methotrexate—Myalgia—Vincristine—colon cancer	7.03e-05	0.0013	CcSEcCtD
Methotrexate—Cough—Irinotecan—colon cancer	7.02e-05	0.0013	CcSEcCtD
Methotrexate—Pneumonia—Capecitabine—colon cancer	6.93e-05	0.00128	CcSEcCtD
Methotrexate—Leukopenia—Fluorouracil—colon cancer	6.9e-05	0.00127	CcSEcCtD
Methotrexate—Infestation—Capecitabine—colon cancer	6.89e-05	0.00127	CcSEcCtD
Methotrexate—Infestation NOS—Capecitabine—colon cancer	6.89e-05	0.00127	CcSEcCtD
Methotrexate—Depression—Capecitabine—colon cancer	6.87e-05	0.00127	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Capecitabine—colon cancer	6.83e-05	0.00126	CcSEcCtD
Methotrexate—Renal failure—Capecitabine—colon cancer	6.77e-05	0.00125	CcSEcCtD
Methotrexate—Discomfort—Irinotecan—colon cancer	6.77e-05	0.00125	CcSEcCtD
Methotrexate—Anaphylactic shock—Vincristine—colon cancer	6.74e-05	0.00125	CcSEcCtD
Methotrexate—Stomatitis—Capecitabine—colon cancer	6.71e-05	0.00124	CcSEcCtD
Methotrexate—Infection—Vincristine—colon cancer	6.7e-05	0.00124	CcSEcCtD
Methotrexate—Conjunctivitis—Capecitabine—colon cancer	6.7e-05	0.00124	CcSEcCtD
Methotrexate—Convulsion—Fluorouracil—colon cancer	6.67e-05	0.00123	CcSEcCtD
Methotrexate—Confusional state—Irinotecan—colon cancer	6.62e-05	0.00122	CcSEcCtD
Methotrexate—Nervous system disorder—Vincristine—colon cancer	6.61e-05	0.00122	CcSEcCtD
Methotrexate—Thrombocytopenia—Vincristine—colon cancer	6.6e-05	0.00122	CcSEcCtD
Methotrexate—Haematuria—Capecitabine—colon cancer	6.57e-05	0.00121	CcSEcCtD
Methotrexate—Anaphylactic shock—Irinotecan—colon cancer	6.56e-05	0.00121	CcSEcCtD
Methotrexate—Chest pain—Fluorouracil—colon cancer	6.56e-05	0.00121	CcSEcCtD
Methotrexate—Myalgia—Fluorouracil—colon cancer	6.56e-05	0.00121	CcSEcCtD
Methotrexate—ABCB1—renal system—colon cancer	6.52e-05	0.00187	CbGeAlD
Methotrexate—Infection—Irinotecan—colon cancer	6.52e-05	0.0012	CcSEcCtD
Methotrexate—Hyperhidrosis—Vincristine—colon cancer	6.52e-05	0.0012	CcSEcCtD
Methotrexate—Hepatobiliary disease—Capecitabine—colon cancer	6.51e-05	0.0012	CcSEcCtD
Methotrexate—Epistaxis—Capecitabine—colon cancer	6.5e-05	0.0012	CcSEcCtD
Methotrexate—Discomfort—Fluorouracil—colon cancer	6.48e-05	0.0012	CcSEcCtD
Methotrexate—Nervous system disorder—Irinotecan—colon cancer	6.44e-05	0.00119	CcSEcCtD
Methotrexate—Agranulocytosis—Capecitabine—colon cancer	6.43e-05	0.00119	CcSEcCtD
Methotrexate—Thrombocytopenia—Irinotecan—colon cancer	6.43e-05	0.00119	CcSEcCtD
Methotrexate—Anorexia—Vincristine—colon cancer	6.42e-05	0.00119	CcSEcCtD
Methotrexate—Hyperhidrosis—Irinotecan—colon cancer	6.35e-05	0.00117	CcSEcCtD
Methotrexate—Confusional state—Fluorouracil—colon cancer	6.34e-05	0.00117	CcSEcCtD
Methotrexate—Hypotension—Vincristine—colon cancer	6.3e-05	0.00116	CcSEcCtD
Methotrexate—Anaphylactic shock—Fluorouracil—colon cancer	6.29e-05	0.00116	CcSEcCtD
Methotrexate—Anorexia—Irinotecan—colon cancer	6.26e-05	0.00116	CcSEcCtD
Methotrexate—Infection—Fluorouracil—colon cancer	6.25e-05	0.00115	CcSEcCtD
Methotrexate—Haemoglobin—Capecitabine—colon cancer	6.21e-05	0.00115	CcSEcCtD
Methotrexate—ABCG2—lymph node—colon cancer	6.2e-05	0.00177	CbGeAlD
Methotrexate—Haemorrhage—Capecitabine—colon cancer	6.18e-05	0.00114	CcSEcCtD
Methotrexate—Hepatitis—Capecitabine—colon cancer	6.18e-05	0.00114	CcSEcCtD
Methotrexate—Nervous system disorder—Fluorouracil—colon cancer	6.17e-05	0.00114	CcSEcCtD
Methotrexate—Thrombocytopenia—Fluorouracil—colon cancer	6.16e-05	0.00114	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Vincristine—colon cancer	6.14e-05	0.00113	CcSEcCtD
Methotrexate—Pharyngitis—Capecitabine—colon cancer	6.14e-05	0.00113	CcSEcCtD
Methotrexate—Hypotension—Irinotecan—colon cancer	6.13e-05	0.00113	CcSEcCtD
Methotrexate—Urinary tract disorder—Capecitabine—colon cancer	6.11e-05	0.00113	CcSEcCtD
Methotrexate—Insomnia—Vincristine—colon cancer	6.1e-05	0.00113	CcSEcCtD
Methotrexate—Urethral disorder—Capecitabine—colon cancer	6.06e-05	0.00112	CcSEcCtD
Methotrexate—Paraesthesia—Vincristine—colon cancer	6.05e-05	0.00112	CcSEcCtD
Methotrexate—Anorexia—Fluorouracil—colon cancer	5.99e-05	0.00111	CcSEcCtD
Methotrexate—Visual impairment—Capecitabine—colon cancer	5.96e-05	0.0011	CcSEcCtD
Methotrexate—Insomnia—Irinotecan—colon cancer	5.94e-05	0.0011	CcSEcCtD
Methotrexate—Paraesthesia—Irinotecan—colon cancer	5.89e-05	0.00109	CcSEcCtD
Methotrexate—Hypotension—Fluorouracil—colon cancer	5.87e-05	0.00109	CcSEcCtD
Methotrexate—Decreased appetite—Vincristine—colon cancer	5.86e-05	0.00108	CcSEcCtD
Methotrexate—Dyspnoea—Irinotecan—colon cancer	5.85e-05	0.00108	CcSEcCtD
Methotrexate—Erythema multiforme—Capecitabine—colon cancer	5.85e-05	0.00108	CcSEcCtD
Methotrexate—Somnolence—Irinotecan—colon cancer	5.84e-05	0.00108	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Vincristine—colon cancer	5.82e-05	0.00108	CcSEcCtD
Methotrexate—Fatigue—Vincristine—colon cancer	5.81e-05	0.00107	CcSEcCtD
Methotrexate—Eye disorder—Capecitabine—colon cancer	5.78e-05	0.00107	CcSEcCtD
Methotrexate—Dyspepsia—Irinotecan—colon cancer	5.78e-05	0.00107	CcSEcCtD
Methotrexate—Tinnitus—Capecitabine—colon cancer	5.77e-05	0.00107	CcSEcCtD
Methotrexate—Pain—Vincristine—colon cancer	5.76e-05	0.00107	CcSEcCtD
Methotrexate—Cardiac disorder—Capecitabine—colon cancer	5.74e-05	0.00106	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Fluorouracil—colon cancer	5.73e-05	0.00106	CcSEcCtD
Methotrexate—Decreased appetite—Irinotecan—colon cancer	5.71e-05	0.00105	CcSEcCtD
Methotrexate—Insomnia—Fluorouracil—colon cancer	5.69e-05	0.00105	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Irinotecan—colon cancer	5.67e-05	0.00105	CcSEcCtD
Methotrexate—Fatigue—Irinotecan—colon cancer	5.66e-05	0.00105	CcSEcCtD
Methotrexate—Paraesthesia—Fluorouracil—colon cancer	5.65e-05	0.00104	CcSEcCtD
Methotrexate—Pain—Irinotecan—colon cancer	5.61e-05	0.00104	CcSEcCtD
Methotrexate—Angiopathy—Capecitabine—colon cancer	5.61e-05	0.00104	CcSEcCtD
Methotrexate—Dyspnoea—Fluorouracil—colon cancer	5.6e-05	0.00104	CcSEcCtD
Methotrexate—Somnolence—Fluorouracil—colon cancer	5.59e-05	0.00103	CcSEcCtD
Methotrexate—Immune system disorder—Capecitabine—colon cancer	5.59e-05	0.00103	CcSEcCtD
Methotrexate—Mediastinal disorder—Capecitabine—colon cancer	5.57e-05	0.00103	CcSEcCtD
Methotrexate—Chills—Capecitabine—colon cancer	5.55e-05	0.00103	CcSEcCtD
Methotrexate—Dyspepsia—Fluorouracil—colon cancer	5.53e-05	0.00102	CcSEcCtD
Methotrexate—Gastrointestinal pain—Vincristine—colon cancer	5.51e-05	0.00102	CcSEcCtD
Methotrexate—Decreased appetite—Fluorouracil—colon cancer	5.46e-05	0.00101	CcSEcCtD
Methotrexate—Alopecia—Capecitabine—colon cancer	5.46e-05	0.00101	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Fluorouracil—colon cancer	5.43e-05	0.001	CcSEcCtD
Methotrexate—Mental disorder—Capecitabine—colon cancer	5.42e-05	0.001	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—colon cancer	5.42e-05	0.00155	CbGeAlD
Methotrexate—Feeling abnormal—Irinotecan—colon cancer	5.41e-05	0.000999	CcSEcCtD
Methotrexate—Malnutrition—Capecitabine—colon cancer	5.38e-05	0.000995	CcSEcCtD
Methotrexate—Erythema—Capecitabine—colon cancer	5.38e-05	0.000995	CcSEcCtD
Methotrexate—Pain—Fluorouracil—colon cancer	5.38e-05	0.000993	CcSEcCtD
Methotrexate—Gastrointestinal pain—Irinotecan—colon cancer	5.37e-05	0.000992	CcSEcCtD
Methotrexate—ABCB1—digestive system—colon cancer	5.35e-05	0.00153	CbGeAlD
Methotrexate—Body temperature increased—Vincristine—colon cancer	5.33e-05	0.000985	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—colon cancer	5.33e-05	0.000985	CcSEcCtD
Methotrexate—Dysgeusia—Capecitabine—colon cancer	5.27e-05	0.000974	CcSEcCtD
Methotrexate—Back pain—Capecitabine—colon cancer	5.21e-05	0.000962	CcSEcCtD
Methotrexate—Abdominal pain—Irinotecan—colon cancer	5.19e-05	0.000959	CcSEcCtD
Methotrexate—Body temperature increased—Irinotecan—colon cancer	5.19e-05	0.000959	CcSEcCtD
Methotrexate—Feeling abnormal—Fluorouracil—colon cancer	5.18e-05	0.000957	CcSEcCtD
Methotrexate—Vision blurred—Capecitabine—colon cancer	5.07e-05	0.000937	CcSEcCtD
Methotrexate—Ill-defined disorder—Capecitabine—colon cancer	4.99e-05	0.000923	CcSEcCtD
Methotrexate—Urticaria—Fluorouracil—colon cancer	4.99e-05	0.000923	CcSEcCtD
Methotrexate—Anaemia—Capecitabine—colon cancer	4.98e-05	0.000919	CcSEcCtD
Methotrexate—Body temperature increased—Fluorouracil—colon cancer	4.97e-05	0.000918	CcSEcCtD
Methotrexate—Hypersensitivity—Vincristine—colon cancer	4.97e-05	0.000918	CcSEcCtD
Methotrexate—ABCB1—bone marrow—colon cancer	4.93e-05	0.00141	CbGeAlD
Methotrexate—Malaise—Capecitabine—colon cancer	4.85e-05	0.000897	CcSEcCtD
Methotrexate—Vertigo—Capecitabine—colon cancer	4.84e-05	0.000894	CcSEcCtD
Methotrexate—Hypersensitivity—Irinotecan—colon cancer	4.84e-05	0.000894	CcSEcCtD
Methotrexate—Asthenia—Vincristine—colon cancer	4.84e-05	0.000894	CcSEcCtD
Methotrexate—Leukopenia—Capecitabine—colon cancer	4.82e-05	0.00089	CcSEcCtD
Methotrexate—ABCB1—vagina—colon cancer	4.72e-05	0.00135	CbGeAlD
Methotrexate—Asthenia—Irinotecan—colon cancer	4.71e-05	0.00087	CcSEcCtD
Methotrexate—Cough—Capecitabine—colon cancer	4.7e-05	0.000868	CcSEcCtD
Methotrexate—Hypersensitivity—Fluorouracil—colon cancer	4.63e-05	0.000856	CcSEcCtD
Methotrexate—Diarrhoea—Vincristine—colon cancer	4.61e-05	0.000852	CcSEcCtD
Methotrexate—Myalgia—Capecitabine—colon cancer	4.58e-05	0.000847	CcSEcCtD
Methotrexate—Arthralgia—Capecitabine—colon cancer	4.58e-05	0.000847	CcSEcCtD
Methotrexate—Chest pain—Capecitabine—colon cancer	4.58e-05	0.000847	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	4.55e-05	0.000841	CcSEcCtD
Methotrexate—Discomfort—Capecitabine—colon cancer	4.53e-05	0.000837	CcSEcCtD
Methotrexate—Diarrhoea—Irinotecan—colon cancer	4.49e-05	0.00083	CcSEcCtD
Methotrexate—Dizziness—Vincristine—colon cancer	4.46e-05	0.000824	CcSEcCtD
Methotrexate—Pruritus—Fluorouracil—colon cancer	4.45e-05	0.000822	CcSEcCtD
Methotrexate—Confusional state—Capecitabine—colon cancer	4.43e-05	0.000819	CcSEcCtD
Methotrexate—Infection—Capecitabine—colon cancer	4.36e-05	0.000806	CcSEcCtD
Methotrexate—Dizziness—Irinotecan—colon cancer	4.34e-05	0.000802	CcSEcCtD
Methotrexate—Nervous system disorder—Capecitabine—colon cancer	4.31e-05	0.000796	CcSEcCtD
Methotrexate—Diarrhoea—Fluorouracil—colon cancer	4.3e-05	0.000795	CcSEcCtD
Methotrexate—Thrombocytopenia—Capecitabine—colon cancer	4.3e-05	0.000795	CcSEcCtD
Methotrexate—Vomiting—Vincristine—colon cancer	4.29e-05	0.000792	CcSEcCtD
Methotrexate—Skin disorder—Capecitabine—colon cancer	4.27e-05	0.000788	CcSEcCtD
Methotrexate—Rash—Vincristine—colon cancer	4.25e-05	0.000785	CcSEcCtD
Methotrexate—Hyperhidrosis—Capecitabine—colon cancer	4.25e-05	0.000785	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—colon cancer	4.25e-05	0.000785	CcSEcCtD
Methotrexate—Headache—Vincristine—colon cancer	4.22e-05	0.00078	CcSEcCtD
Methotrexate—Anorexia—Capecitabine—colon cancer	4.19e-05	0.000774	CcSEcCtD
Methotrexate—Vomiting—Irinotecan—colon cancer	4.17e-05	0.000771	CcSEcCtD
Methotrexate—Dizziness—Fluorouracil—colon cancer	4.16e-05	0.000768	CcSEcCtD
Methotrexate—Rash—Irinotecan—colon cancer	4.14e-05	0.000765	CcSEcCtD
Methotrexate—Dermatitis—Irinotecan—colon cancer	4.13e-05	0.000764	CcSEcCtD
Methotrexate—Headache—Irinotecan—colon cancer	4.11e-05	0.00076	CcSEcCtD
Methotrexate—Hypotension—Capecitabine—colon cancer	4.11e-05	0.000759	CcSEcCtD
Methotrexate—Nausea—Vincristine—colon cancer	4e-05	0.00074	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Capecitabine—colon cancer	4e-05	0.00074	CcSEcCtD
Methotrexate—Vomiting—Fluorouracil—colon cancer	4e-05	0.000739	CcSEcCtD
Methotrexate—ABCB1—liver—colon cancer	3.99e-05	0.00114	CbGeAlD
Methotrexate—Insomnia—Capecitabine—colon cancer	3.97e-05	0.000734	CcSEcCtD
Methotrexate—Rash—Fluorouracil—colon cancer	3.96e-05	0.000732	CcSEcCtD
Methotrexate—Dermatitis—Fluorouracil—colon cancer	3.96e-05	0.000732	CcSEcCtD
Methotrexate—Paraesthesia—Capecitabine—colon cancer	3.94e-05	0.000729	CcSEcCtD
Methotrexate—Headache—Fluorouracil—colon cancer	3.94e-05	0.000728	CcSEcCtD
Methotrexate—Dyspnoea—Capecitabine—colon cancer	3.92e-05	0.000724	CcSEcCtD
Methotrexate—Nausea—Irinotecan—colon cancer	3.9e-05	0.00072	CcSEcCtD
Methotrexate—Dyspepsia—Capecitabine—colon cancer	3.87e-05	0.000715	CcSEcCtD
Methotrexate—Decreased appetite—Capecitabine—colon cancer	3.82e-05	0.000706	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Capecitabine—colon cancer	3.79e-05	0.000701	CcSEcCtD
Methotrexate—Fatigue—Capecitabine—colon cancer	3.79e-05	0.0007	CcSEcCtD
Methotrexate—Pain—Capecitabine—colon cancer	3.76e-05	0.000694	CcSEcCtD
Methotrexate—Nausea—Fluorouracil—colon cancer	3.73e-05	0.00069	CcSEcCtD
Methotrexate—Feeling abnormal—Capecitabine—colon cancer	3.62e-05	0.000669	CcSEcCtD
Methotrexate—Gastrointestinal pain—Capecitabine—colon cancer	3.59e-05	0.000664	CcSEcCtD
Methotrexate—Urticaria—Capecitabine—colon cancer	3.49e-05	0.000645	CcSEcCtD
Methotrexate—Abdominal pain—Capecitabine—colon cancer	3.47e-05	0.000642	CcSEcCtD
Methotrexate—Body temperature increased—Capecitabine—colon cancer	3.47e-05	0.000642	CcSEcCtD
Methotrexate—Hypersensitivity—Capecitabine—colon cancer	3.24e-05	0.000598	CcSEcCtD
Methotrexate—Asthenia—Capecitabine—colon cancer	3.15e-05	0.000582	CcSEcCtD
Methotrexate—Pruritus—Capecitabine—colon cancer	3.11e-05	0.000574	CcSEcCtD
Methotrexate—ABCB1—lymph node—colon cancer	3.06e-05	0.000874	CbGeAlD
Methotrexate—Diarrhoea—Capecitabine—colon cancer	3.01e-05	0.000555	CcSEcCtD
Methotrexate—Dizziness—Capecitabine—colon cancer	2.91e-05	0.000537	CcSEcCtD
Methotrexate—Vomiting—Capecitabine—colon cancer	2.79e-05	0.000516	CcSEcCtD
Methotrexate—Rash—Capecitabine—colon cancer	2.77e-05	0.000512	CcSEcCtD
Methotrexate—Dermatitis—Capecitabine—colon cancer	2.77e-05	0.000511	CcSEcCtD
Methotrexate—Headache—Capecitabine—colon cancer	2.75e-05	0.000509	CcSEcCtD
Methotrexate—Nausea—Capecitabine—colon cancer	2.61e-05	0.000482	CcSEcCtD
Methotrexate—DHFR—Disease—FGFR3—colon cancer	7.99e-06	0.000362	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—colon cancer	7.96e-06	0.000361	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	7.94e-06	0.00036	CbGpPWpGaD
Methotrexate—PGD—Disease—EP300—colon cancer	7.9e-06	0.000358	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—colon cancer	7.88e-06	0.000357	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—EP300—colon cancer	7.88e-06	0.000357	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—colon cancer	7.87e-06	0.000357	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ABCB1—colon cancer	7.76e-06	0.000352	CbGpPWpGaD
Methotrexate—MTHFR—Disease—BRAF—colon cancer	7.76e-06	0.000352	CbGpPWpGaD
Methotrexate—PGD—Disease—SRC—colon cancer	7.68e-06	0.000349	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—colon cancer	7.68e-06	0.000348	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—TYMS—colon cancer	7.62e-06	0.000346	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—colon cancer	7.62e-06	0.000346	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—colon cancer	7.59e-06	0.000344	CbGpPWpGaD
Methotrexate—AOX1—Disease—BRAF—colon cancer	7.58e-06	0.000344	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TGFB1—colon cancer	7.58e-06	0.000344	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.57e-06	0.000343	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.54e-06	0.000342	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—colon cancer	7.53e-06	0.000341	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFB1—colon cancer	7.51e-06	0.000341	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ABCB1—colon cancer	7.44e-06	0.000337	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—colon cancer	7.39e-06	0.000335	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—colon cancer	7.36e-06	0.000334	CbGpPWpGaD
Methotrexate—DHFR—Disease—APC—colon cancer	7.34e-06	0.000333	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—EP300—colon cancer	7.24e-06	0.000328	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.16e-06	0.000325	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—KRAS—colon cancer	7.02e-06	0.000318	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.97e-06	0.000316	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KRAS—colon cancer	6.96e-06	0.000316	CbGpPWpGaD
Methotrexate—DHFR—Disease—BRAF—colon cancer	6.9e-06	0.000313	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—colon cancer	6.89e-06	0.000312	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PIK3CA—colon cancer	6.87e-06	0.000312	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PIK3CA—colon cancer	6.87e-06	0.000312	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFB1—colon cancer	6.87e-06	0.000312	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—colon cancer	6.87e-06	0.000311	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ABCB1—colon cancer	6.82e-06	0.000309	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	6.75e-06	0.000306	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—colon cancer	6.73e-06	0.000305	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—colon cancer	6.7e-06	0.000304	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TYMS—colon cancer	6.7e-06	0.000304	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PPARG—colon cancer	6.67e-06	0.000303	CbGpPWpGaD
Methotrexate—PGD—Metabolism—EP300—colon cancer	6.62e-06	0.0003	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—colon cancer	6.6e-06	0.000299	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.59e-06	0.000299	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PPARG—colon cancer	6.52e-06	0.000296	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—EP300—colon cancer	6.5e-06	0.000295	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—colon cancer	6.46e-06	0.000293	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CA—colon cancer	6.45e-06	0.000292	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PIK3CA—colon cancer	6.39e-06	0.00029	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—colon cancer	6.36e-06	0.000289	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SRC—colon cancer	6.32e-06	0.000287	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.29e-06	0.000285	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	6.27e-06	0.000284	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—colon cancer	6.27e-06	0.000284	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—colon cancer	6.24e-06	0.000283	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ABCB1—colon cancer	6.16e-06	0.000279	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—colon cancer	6.15e-06	0.000279	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—colon cancer	6.12e-06	0.000278	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	6.1e-06	0.000277	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—colon cancer	6.08e-06	0.000276	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TYMS—colon cancer	6.05e-06	0.000274	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.04e-06	0.000274	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—colon cancer	5.96e-06	0.000271	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PPARG—colon cancer	5.93e-06	0.000269	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.93e-06	0.000269	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—colon cancer	5.91e-06	0.000268	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	5.9e-06	0.000268	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—colon cancer	5.85e-06	0.000265	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TGFB1—colon cancer	5.65e-06	0.000256	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—colon cancer	5.64e-06	0.000256	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.63e-06	0.000256	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	5.62e-06	0.000255	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—colon cancer	5.61e-06	0.000255	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—colon cancer	5.61e-06	0.000255	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—colon cancer	5.61e-06	0.000254	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	5.59e-06	0.000254	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—colon cancer	5.57e-06	0.000253	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	5.55e-06	0.000252	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1A—colon cancer	5.48e-06	0.000248	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.48e-06	0.000248	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—colon cancer	5.48e-06	0.000248	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	5.46e-06	0.000248	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—colon cancer	5.41e-06	0.000245	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	5.4e-06	0.000245	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—colon cancer	5.4e-06	0.000245	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—colon cancer	5.36e-06	0.000243	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—colon cancer	5.35e-06	0.000243	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1A—colon cancer	5.35e-06	0.000243	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	5.32e-06	0.000241	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—colon cancer	5.27e-06	0.000239	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TYMS—colon cancer	5.26e-06	0.000239	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—colon cancer	5.25e-06	0.000238	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—colon cancer	5.23e-06	0.000237	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—colon cancer	5.22e-06	0.000237	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EP300—colon cancer	5.21e-06	0.000236	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—colon cancer	5.17e-06	0.000235	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.16e-06	0.000234	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—colon cancer	5.13e-06	0.000233	CbGpPWpGaD
Methotrexate—AOX1—Disease—EP300—colon cancer	5.09e-06	0.000231	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SRC—colon cancer	5.07e-06	0.00023	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—colon cancer	4.98e-06	0.000226	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	4.96e-06	0.000225	CbGpPWpGaD
Methotrexate—AOX1—Disease—SRC—colon cancer	4.95e-06	0.000225	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.93e-06	0.000224	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—colon cancer	4.9e-06	0.000222	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	4.89e-06	0.000222	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	4.88e-06	0.000221	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—colon cancer	4.88e-06	0.000221	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1A—colon cancer	4.87e-06	0.000221	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—colon cancer	4.82e-06	0.000219	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—colon cancer	4.81e-06	0.000218	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	4.79e-06	0.000217	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—colon cancer	4.78e-06	0.000217	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—colon cancer	4.76e-06	0.000216	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—colon cancer	4.75e-06	0.000215	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TYMS—colon cancer	4.74e-06	0.000215	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.69e-06	0.000212	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—colon cancer	4.66e-06	0.000212	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.65e-06	0.000211	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—colon cancer	4.65e-06	0.000211	CbGpPWpGaD
Methotrexate—DHFR—Disease—EP300—colon cancer	4.63e-06	0.00021	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—colon cancer	4.58e-06	0.000208	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—colon cancer	4.54e-06	0.000206	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—colon cancer	4.53e-06	0.000206	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	4.52e-06	0.000205	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR3—colon cancer	4.52e-06	0.000205	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—colon cancer	4.5e-06	0.000204	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TYMS—colon cancer	4.5e-06	0.000204	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—colon cancer	4.45e-06	0.000202	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—colon cancer	4.44e-06	0.000202	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—colon cancer	4.44e-06	0.000201	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—colon cancer	4.43e-06	0.000201	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—colon cancer	4.37e-06	0.000198	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—EP300—colon cancer	4.37e-06	0.000198	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—colon cancer	4.34e-06	0.000197	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—colon cancer	4.33e-06	0.000197	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—colon cancer	4.28e-06	0.000194	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—colon cancer	4.26e-06	0.000193	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—colon cancer	4.25e-06	0.000193	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—colon cancer	4.24e-06	0.000193	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	4.22e-06	0.000191	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—colon cancer	4.2e-06	0.00019	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TYMS—colon cancer	4.17e-06	0.000189	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.15e-06	0.000188	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—colon cancer	4.15e-06	0.000188	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—colon cancer	4.1e-06	0.000186	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.09e-06	0.000186	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—colon cancer	4.07e-06	0.000185	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.05e-06	0.000184	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—colon cancer	4.04e-06	0.000183	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—colon cancer	4.03e-06	0.000183	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.02e-06	0.000182	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—colon cancer	4e-06	0.000181	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—colon cancer	3.95e-06	0.000179	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—colon cancer	3.93e-06	0.000178	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—colon cancer	3.9e-06	0.000177	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—colon cancer	3.88e-06	0.000176	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—colon cancer	3.86e-06	0.000175	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—colon cancer	3.77e-06	0.000171	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—colon cancer	3.73e-06	0.000169	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—colon cancer	3.73e-06	0.000169	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—colon cancer	3.73e-06	0.000169	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.65e-06	0.000165	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—colon cancer	3.57e-06	0.000162	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—colon cancer	3.53e-06	0.00016	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—colon cancer	3.48e-06	0.000158	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.47e-06	0.000157	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	3.45e-06	0.000156	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—colon cancer	3.43e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.39e-06	0.000154	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—colon cancer	3.39e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—colon cancer	3.37e-06	0.000153	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—colon cancer	3.36e-06	0.000152	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—colon cancer	3.23e-06	0.000146	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.22e-06	0.000146	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—colon cancer	3.19e-06	0.000145	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—colon cancer	3.17e-06	0.000144	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—colon cancer	3.15e-06	0.000143	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—colon cancer	3.15e-06	0.000143	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—colon cancer	3.15e-06	0.000143	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—colon cancer	3.11e-06	0.000141	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—colon cancer	3.08e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—colon cancer	2.95e-06	0.000134	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—colon cancer	2.94e-06	0.000133	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—colon cancer	2.93e-06	0.000133	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—colon cancer	2.87e-06	0.00013	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—colon cancer	2.86e-06	0.00013	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—colon cancer	2.82e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—colon cancer	2.8e-06	0.000127	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—colon cancer	2.8e-06	0.000127	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—colon cancer	2.78e-06	0.000126	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—colon cancer	2.76e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—colon cancer	2.75e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.68e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—colon cancer	2.64e-06	0.00012	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—colon cancer	2.64e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—colon cancer	2.62e-06	0.000119	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—colon cancer	2.62e-06	0.000119	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—colon cancer	2.61e-06	0.000119	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—colon cancer	2.58e-06	0.000117	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—colon cancer	2.57e-06	0.000117	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—colon cancer	2.56e-06	0.000116	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—colon cancer	2.55e-06	0.000116	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—colon cancer	2.51e-06	0.000114	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—colon cancer	2.5e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—colon cancer	2.45e-06	0.000111	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—colon cancer	2.44e-06	0.000111	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—colon cancer	2.37e-06	0.000107	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—colon cancer	2.34e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—colon cancer	2.32e-06	0.000105	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—colon cancer	2.3e-06	0.000104	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—colon cancer	2.28e-06	0.000104	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—colon cancer	2.28e-06	0.000103	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—colon cancer	2.25e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—colon cancer	2.23e-06	0.000101	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—colon cancer	2.2e-06	9.96e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—colon cancer	2.18e-06	9.87e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—colon cancer	2.14e-06	9.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—colon cancer	2.11e-06	9.57e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—colon cancer	2.1e-06	9.54e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—colon cancer	2.09e-06	9.46e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—colon cancer	2.07e-06	9.4e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—colon cancer	2.05e-06	9.28e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—colon cancer	2.01e-06	9.13e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.98e-06	8.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—colon cancer	1.94e-06	8.8e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—colon cancer	1.93e-06	8.76e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—colon cancer	1.88e-06	8.51e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—colon cancer	1.82e-06	8.26e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—colon cancer	1.8e-06	8.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—colon cancer	1.79e-06	8.14e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—colon cancer	1.78e-06	8.06e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—colon cancer	1.69e-06	7.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—colon cancer	1.62e-06	7.37e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—colon cancer	1.6e-06	7.24e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—colon cancer	1.58e-06	7.19e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—colon cancer	1.54e-06	7e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—colon cancer	1.47e-06	6.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—colon cancer	1.43e-06	6.5e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—colon cancer	1.43e-06	6.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—colon cancer	1.33e-06	6.02e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—colon cancer	1.26e-06	5.72e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—colon cancer	1.26e-06	5.7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—colon cancer	1.19e-06	5.41e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—colon cancer	1.17e-06	5.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—colon cancer	1.04e-06	4.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—colon cancer	8.82e-07	4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—colon cancer	7.73e-07	3.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—colon cancer	7.2e-07	3.27e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—colon cancer	6.31e-07	2.86e-05	CbGpPWpGaD
